These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26401573)

  • 1. Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer's Disease.
    Giil LM; Kristoffersen EK; Vedeler CA; Aarsland D; Nordrehaug JE; Winblad B; Cedazo-Minguez A; Lund A; Reksten TR
    J Alzheimers Dis; 2015; 47(2):523-9. PubMed ID: 26401573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease.
    Sarlus H; Eyjolfsdottir H; Eriksdotter M; Oprica M; Schultzberg M
    J Alzheimers Dis; 2015; 48(2):495-505. PubMed ID: 26402013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AT2R autoantibodies block angiotensin II and AT1R autoantibody-induced vasoconstriction.
    Liles C; Li H; Veitla V; Liles JT; Murphy TA; Cunningham MW; Yu X; Kem DC
    Hypertension; 2015 Oct; 66(4):830-5. PubMed ID: 26259590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-ETAR and anti-AT1R autoantibodies are elevated in patients with endstage cystic fibrosis.
    Budding K; van de Graaf EA; Hoefnagel T; Kwakkel-van Erp JM; van Kessel DA; Dragun D; Hack CE; Otten HG
    J Cyst Fibros; 2015 Jan; 14(1):42-5. PubMed ID: 25096855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galanin and α-MSH autoantibodies in cerebrospinal fluid of patients with Alzheimer's disease.
    Costa A; Bini P; Hamze-Sinno M; Moglia A; Franciotta D; Sinforiani E; Ravaglia S; Bole-Feysot C; Hökfelt T; Déchelotte P; Fetissov SO
    J Neuroimmunol; 2011 Dec; 240-241():114-20. PubMed ID: 22078238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiopathic normal pressure hydrocephalus has a different cerebrospinal fluid biomarker profile from Alzheimer's disease.
    Jingami N; Asada-Utsugi M; Uemura K; Noto R; Takahashi M; Ozaki A; Kihara T; Kageyama T; Takahashi R; Shimohama S; Kinoshita A
    J Alzheimers Dis; 2015; 45(1):109-15. PubMed ID: 25428256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A relationship between Alzheimer's disease and type 2 diabetes mellitus through the measurement of serum amyloid-beta autoantibodies.
    Kim I; Lee J; Hong HJ; Jung ES; Ku YH; Jeong IK; Cho YM; So I; Park KS; Mook-Jung I
    J Alzheimers Dis; 2010; 19(4):1371-6. PubMed ID: 20061608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.
    Maetzler W; Berg D; Synofzik M; Brockmann K; Godau J; Melms A; Gasser T; Hörnig S; Langkamp M
    J Alzheimers Dis; 2011; 26(1):171-9. PubMed ID: 21593566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
    Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
    J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropsychological and behavioural correlates of CSF biomarkers in dementia.
    Engelborghs S; Maertens K; Vloeberghs E; Aerts T; Somers N; Mariën P; De Deyn PP
    Neurochem Int; 2006 Mar; 48(4):286-95. PubMed ID: 16434124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Putative autoantibodies in the cerebrospinal fluid of Alzheimer's disease patients.
    Lim B; Tsolaki M; Batruch I; Anastasiou A; Frontistis A; Prassas I; Diamandis EP
    F1000Res; 2019; 8():1900. PubMed ID: 32089828
    [No Abstract]   [Full Text] [Related]  

  • 16. Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
    Skillbäck T; Farahmand BY; Rosén C; Mattsson N; Nägga K; Kilander L; Religa D; Wimo A; Winblad B; Schott JM; Blennow K; Eriksdotter M; Zetterberg H
    Brain; 2015 Sep; 138(Pt 9):2716-31. PubMed ID: 26133663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia--a study from Southern India.
    Huded CB; Bharath S; Chandra SR; Sivakumar PT; Varghese M; Subramanian S
    Asian J Psychiatr; 2015 Feb; 13():44-7. PubMed ID: 25468261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
    Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE
    Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers.
    Slats D; Claassen JA; Spies PE; Borm G; Besse KT; van Aalst W; Tseng J; Sjögren MJ; Olde Rikkert MG; Verbeek MM
    Neurobiol Aging; 2012 Apr; 33(4):831.e1-9. PubMed ID: 21880396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated IgM against Nε-(Carboxyethyl)lysine-modified Apolipoprotein A1 peptide 141-147 in Taiwanese with Alzheimer's disease.
    Lin CY; Sheu JJ; Tsai IS; Wang ST; Yang LY; Hsu IU; Chang HW; Lee HM; Kao SH; Lee CK; Chen CH; Lin YF
    Clin Biochem; 2018 Jun; 56():75-82. PubMed ID: 29680706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.